Robert W. Baird Issues Pessimistic Forecast for Cigna Group (NYSE:CI) Stock Price

Cigna Group (NYSE:CI) had its price target reduced by equities research analysts at Robert W. Baird from $315.00 to $306.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the health services provider’s stock. Robert W. Baird’s price objective points to a potential upside of 10.80% from the stock’s previous close.

CI has been the subject of several other reports. Wall Street Zen raised Cigna Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Sanford C. Bernstein upgraded Cigna Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $307.00 to $358.00 in a research note on Thursday, March 12th. Truist Financial boosted their target price on Cigna Group from $320.00 to $350.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Piper Sandler decreased their target price on Cigna Group from $374.00 to $370.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Cigna Group from $301.00 to $304.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $332.63.

Cigna Group Stock Up 2.8%

NYSE CI opened at $276.17 on Wednesday. The business has a fifty day moving average price of $276.17 and a 200 day moving average price of $278.22. Cigna Group has a one year low of $239.51 and a one year high of $350.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.74 and a current ratio of 0.74. The company has a market cap of $72.78 billion, a P/E ratio of 12.45, a P/E/G ratio of 0.93 and a beta of 0.26.

Cigna Group (NYSE:CI) last posted its quarterly earnings data on Thursday, February 5th. The health services provider reported $8.08 EPS for the quarter, beating the consensus estimate of $7.88 by $0.20. Cigna Group had a return on equity of 19.46% and a net margin of 2.17%.The firm had revenue of $72.50 billion during the quarter, compared to the consensus estimate of $69.53 billion. During the same period in the prior year, the company earned $6.64 EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.250- EPS. Research analysts anticipate that Cigna Group will post 29.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cigna Group news, insider Everett Neville sold 1,719 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $496,636.29. Following the sale, the insider directly owned 5,670 shares in the company, valued at approximately $1,638,119.70. The trade was a 23.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicole S. Jones sold 2,307 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total value of $666,515.37. Following the sale, the insider owned 32,647 shares in the company, valued at approximately $9,432,044.77. The trade was a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Cigna Group

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Armstrong Advisory Group Inc. lifted its position in shares of Cigna Group by 17.7% in the third quarter. Armstrong Advisory Group Inc. now owns 226 shares of the health services provider’s stock valued at $65,000 after acquiring an additional 34 shares in the last quarter. HM Payson & Co. lifted its position in shares of Cigna Group by 0.9% in the third quarter. HM Payson & Co. now owns 3,785 shares of the health services provider’s stock valued at $1,091,000 after acquiring an additional 35 shares in the last quarter. Carr Financial Group Corp lifted its position in shares of Cigna Group by 5.3% in the third quarter. Carr Financial Group Corp now owns 709 shares of the health services provider’s stock valued at $204,000 after acquiring an additional 36 shares in the last quarter. Natural Investments LLC lifted its position in shares of Cigna Group by 2.0% in the third quarter. Natural Investments LLC now owns 1,843 shares of the health services provider’s stock valued at $531,000 after acquiring an additional 36 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of Cigna Group by 11.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 363 shares of the health services provider’s stock valued at $100,000 after acquiring an additional 36 shares in the last quarter. 86.99% of the stock is currently owned by hedge funds and other institutional investors.

About Cigna Group

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.